Purple Biotech Ltd.(PPBT)Earnings, Financials & Key Ratios
PPBT•NASDAQ
$1.68
Price updated Jun 27, 2026
AboutPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Show more
- Revenue$0
- EBITDA-$27M-151.9%
- Net Income-$26M-264.4%
- EPS (Diluted)-11080.00-24967.9%
- ROE-123.97%-475.4%
PPBT Price & Volume
Purple Biotech Ltd. (PPBT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity depletion
Key Thesis Takeaways
- Purple Biotech remains a high-risk, pre-revenue clinical-stage entity characterized by a consistent erosion of its capital base and a lack of sustainable internal funding.
- The company's reliance on external capital to support its oncology pipeline is underscored by a cumulative retained earnings deficit of $171.2 million as of 2026Q1.
- Investors should remain cautious as the current cash position of $5.6 million provides a limited buffer against ongoing R&D expenditures, necessitating potential future dilution to maintain operations.
Verdict Logic
the company's cash and equivalents have dwindled to $5.6 million as of 2026Q1, suggesting an imminent risk of liquidity depletion that may require dilutive financing to sustain operations.
PPBT Growth Metrics
Purple Biotech Ltd. (PPBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-566.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-39635.76%
Return on Capital
10 Years-60.38%
5 Years-55.27%
3 Years-70.69%
Last Year-128.1%
PPBT Recent Earnings
Purple Biotech Ltd. (PPBT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (27%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.09+76.3%
$0.38
Rev
—
—
Q2 2026
Mar 13, 2026Metric
Actual
Est
EPS
$19.85-483.8%
$3.40
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.29-11.5%
$0.26
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.40-90.5%
$0.21
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.09vs $0.38+76.3% | — |
| Q2 2026 | Mar 13, 2026 | $19.85vs $3.40-483.8% | — |
| Q4 2025 | Nov 14, 2025 | $0.29vs $0.26-11.5% | — |
| Q3 2025 | Aug 6, 2025 | $0.40vs $0.21-90.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Purple Biotech Ltd. (PPBT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.68 | $7.81K | -0.00 | — | — | -123.97% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $1.02 | $129.73M | -0.91 | 14.85% | -173.02% | — | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — |
Compare PPBT vs Peers
Purple Biotech Ltd. (PPBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PPBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PPBT Frequently Asked Questions
Purple Biotech Ltd. (PPBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PPBT profitable?
Purple Biotech Ltd. (PPBT) reported a net loss of $26.2M for fiscal year 2025.
Dividend & Returns
What is PPBT's return on equity?
Purple Biotech Ltd. (PPBT) has a return on equity (ROE) of -124.0%. Negative ROE indicates the company is unprofitable.
What is Purple Biotech Ltd.'s free cash flow?
Purple Biotech Ltd. (PPBT) had negative free cash flow of $4.7M in fiscal year 2025, likely due to heavy capital investments.